COVID-19
Conditions
Keywords
COVID-19, siRNA, SARS-CoV-2
Brief summary
This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of MIR 19® via 14 days of treatment of participants with symptomatic moderate COVID-19. The purpose of this study is to evaluate the efficacy, safety and daily dose of MIR 19 ® for the treatment of the hospitalized patients with infection caused by SARS-CoV-2 (COVID-19) who did not require treatment in the intensive care unit. Based on preclinical data studying antiviral effect of MIR 19® in vitro and in vivo (Khaitov M.R. et all 2021), the investigators hypothesized that SARS-CoV-2 inhibition with MIR 19® could potentially reduce pulmonary inflammation, thereby improving COVID-19 patient outcomes.
Detailed description
This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of MIR 19 ® in male and female volunteers with symptomatic moderate COVID-19 who did not require treatment in the intensive care unit. The MIR 19® is a complex of siRNA, targeting SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and peptide dendrimer KK-46. This study involved 3 cohorts who received: 1. standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. 2. 3.7 mg of the MIR 19 ® via inhalation route plus standard therapy which included symptomatic treatment, without any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. 3. 11.1 mg of the MIR 19 ® via inhalation route plus standard therapy which included symptomatic treatment, without any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. All subjects will undergo scheduled safety and efficacy assessments while in the clinical unit and as outpatients to the end of the follow-up period.
Interventions
DRUGMIR 19 ®
Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
COMBINATION_PRODUCTStandard COVID-19 therapy
Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
Sponsors
St. Petersburg Research Institute of Vaccines and Sera
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Men or non-pregnant female aged 18 to 65 years hospitalized with moderate COVID-19 infection: body temperature \> 37.5 °C; respiratory rate \> 22/min; shortness of breath during physical exertion; typical coronavirus-associated chest computed tomography (CT) changes (CT1- CT2); pulse oximetry levels SpO2\< 95%. 2. Able to give informed consent and attend all study visits 3. Positive PCR-test for COVID-19 ≤72 hours prior to randomization 4. The patient's ability to inhale the experimental drug 5. Participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month Key
Exclusion criteria
1. Fever \> 38.5°C. 2. Cough severity is less than 1 point on a 4-point scale. 3. Respiratory rate \> is more than 30 / min 4. SpO2 ≤ 93%. 5. Decreased level of consciousness, agitation. 6. Unstable hemodynamics (systolic blood pressure less than 100 mmHg or diastolic blood pressure less than 60 mmHg). 7. The need to require mechanical ventilation beyond the screening/ randomization. 8. Long-term systemic corticosteroid exposure. 9. Autoimmune or inflammatory diseases (systemic / localized). 10. Positive blood tests for HIV, hepatitis B and С, syphilis. 11. Pregnancy and breast-feeding 12. Previous adverse reactions to the active substance and/or excipients included in the drug. 13. Any use of anti-viral medications or immunomodulatory agents up to 7 days before participating in the study 14. Chronic diseases of the cardiovascular system 15. Type 1 diabetes 16. The following laboratory parameters are excluded: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total and direct bilirubin \>4 x upper limit of normal (ULN); 17. Treatment with any medicine that have a pronounced effects on the blood coagulation system (expect for COVID-19 treatment), including combined oral contraceptives. 18. Treatment with any medicine that can affect cardiac conduction 19. Participation in other investigational drug or device clinical trials within 90 days prior to screening. 20. History of alcohol, drug or chemical abuse. 21. Mental illness. 22. Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) up to 14 days before participating in the study, vaccination against SARS-CoV-2 , the need for extracorporeal membrane oxygenation. 23. Any conditions that, according to the researcher's, may be a contraindication to the participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relief of fever | Within 14 days | Reduction in axillary temperature below 37 °C without antipyretic drugs use |
| Respiratory rate | Within 14 days | Respiratory rate ≤ 22 per minute |
| Oxygen saturation | Within 14 days | SpO2 \> 94% |
| Severity of cough | Within 14 days | Severity in a patient's cough no more than 1 point on a four-point scale |
Countries
Russia
Outcome results
None listed